Key Takeaways:
Cypherpunk Technologies posted $39.4 million net income in Q2 2026, reversing a $16.6 million loss a year earlier, after a $46 million unrealized gain on its Zcash holdings.
"In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity," Will McEvoy, chief investment officer at Cypherpunk, said. "Our execution in the second quarter reinforces Cypherpunk's conviction in Zcash as a foundational monetary asset."
ZEC rose from $243.35 to $400.09 during the quarter, lifting the Cambridge, Massachusetts-based company's digital assets receivable to $129.4 million. Cypherpunk held 323,394.38 ZEC as of Aug. 11 at an average purchase price of $341.83, representing about 1.92% of the Zcash network's circulating supply, according to the company's earnings release.
The swing shows the volatility of a single-asset crypto treasury. In Q1 2026, Cypherpunk posted a $77.2 million net loss after ZEC cratered from about $508 to roughly $240, and its accumulated deficit stood at $500.3 million at June 30. Whether ZEC holds above the $341.83 average acquisition cost determines whether the next quarter repeats the gain or the loss.
From oncology to a Zcash treasury
Cypherpunk, which trades on Nasdaq under the ticker CYPH, operated as Leap Therapeutics, an oncology-focused biotech, before rebranding in November 2025 and pivoting to a ZEC-centric treasury strategy. Winklevoss Capital spearheaded a private placement that funded the token accumulation, while the company retains its legacy cancer research through the Leap Therapeutics subsidiary.
The pivot reshaped the income statement. Research and development expenses fell to $0.2 million from $10.5 million as clinical trials wound down and headcount was cut, while general and administrative costs rose to $4.5 million from $1.8 million on higher stock-based compensation. Cash and equivalents dropped to $7.6 million from $14.0 million at the end of 2025.
Biotech arm advances alongside the treasury
Leap Therapeutics reached alignment with the FDA on a proposed Phase 3 trial of sirexatamab in DKK1-high, second-line metastatic colorectal cancer, after the agency granted Fast Track designation in May. The company said it is weighing whether to finance the program as an independent spin-out or pursue a partnership, and it has not set a timetable.
For investors weighing CYPH as a proxy for Zcash exposure, the question is whether the public-market wrapper — liquidity, brokerage access, potential tax treatment — justifies the corporate overhead and governance risk. The company also appointed Dev Ojha, founder of the Zcash-focused Valar Group, as an advisor, joining Zcash founder Zooko Wilcox on its advisory team.
This article is for informational purposes only and does not constitute investment advice.
